|
López-Cuenca A, Marín F, Roldán V, González-Conejero R, Hernández-Romero D, Valdés M, Lip GY. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010 Dec;42(8):562-75. doi: 10.3109/07853890.2010.507601. Epub 2010 Aug 4. Review. PubMed PMID: 20681943.
AÑO: 2010; IF: 4.323
|
20681943
|
Moreno V, Hernández-Romero D, Vilchez JA, García-Honrubia A, Cambronero F, Casas T, González J, Martínez P, Climent V, de la Morena G, Valdés M, Marín F. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail. 2010 Dec;16(12):950-6. doi: 10.1016/j.cardfail.2010.07.245. PubMed PMID: 21111984.
AÑO: 2010; IF: 3.362
|
|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|
|
Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F. Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):521-30. doi: 10.1177/1470320311405247. Epub 2011 Apr 20. Review. PubMed PMID: 21507890.
AÑO: 2011; IF: 2.439
|
|
Orenes-Piñero E, Hernández-Romero D, Jover E, de la Morena G, Valdés M, Marín F. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy. Med Chem. 2011 Jul;7(4):275-85. Review. PubMed PMID: 21568880.
AÑO: 2011; IF: 1.496
|